Rhythm Pharmaceuticals (RYTM) and Axovia Therapeutics announced a joint research collaboration designed to advance the understanding of Bardet-Biedl syndrome, or BBS. BBS is a rare autosomal recessive ciliopathy that presents with a variety of signs and symptoms that evolve over time including visual impairment, renal disease, polydactyly, genital abnormalities, cognitive impairment, hyperphagia and early-onset, severe obesity arising from impairment of the hypothalamic MC4R pathway. In the United States, BBS affects approximately 4,000 to 5,000 individuals with similar prevalence in Europe.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $52 from $48 at BofA
- Biotech Alert: Searches spiking for these stocks today
- Rhythm Pharmaceuticals initiated with a Buy at H.C. Wainwright
- Shopify upgraded, SolarEdge downgraded: Wall Street’s top analyst calls
- Rhythm Pharmaceuticals initiated with an Outperform at JMP Securities